biote Corp.

BTMD

US0906831039

Professional Information Services

Real-time Estimate Cboe BZX Other stock markets 10:22:42 2024-07-09 am EDT			5-day change	1st Jan Change
7.505 ^USD	+1.56%		-2.48%	+51.01%

Jul. 01	Biote Corp.(NasdaqGM:BTMD) dropped from Russell 2000 Value-Defensive Index	CI
Jul. 01	Biote Corp.(NasdaqGM:BTMD) dropped from Russell 2000 Growth-Defensive Index	CI

Biote Corp. authorizes a Buyback Plan.

June 19, 2024

The Board of Directors of biote Corp. has authorized a buyback plan on June 20, 2024.

Latest news about biote Corp.

Biote Corp.(NasdaqGM:BTMD) dropped from Russell 2000 Value-Defensive Index	Jun. 30	CI
Biote Corp.(NasdaqGM:BTMD) dropped from Russell 2000 Growth-Defensive Index	Jun. 30	CI
Biote Corp.(NasdaqGM:BTMD) dropped from Russell 2000 Defensive Index	Jun. 30	CI
Biote Reaches $60 Million Settlement to Repurchase Shares From Stockholder	Jun. 20	MT
Biote Corp. announces an Equity Buyback for 8,300,000 shares, for $60 million.	Jun. 20	CI
Biote Corp. authorizes a Buyback Plan.	Jun. 19	CI
Biote Shares Fall After Report by Short-Seller J Capital	May. 20	MT
Biote Corp. acquired Certain assets of BioSana ID LLC for $0.8 million.	May. 09	CI
Earnings Flash (BTMD) BIOTE Reports Q1 Revenue $46.8M, vs. Street Est of $45.7M	May. 07	MT
Transcript : Biote Corp., Q1 2024 Earnings Call, May 07, 2024	May. 07
Biote Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Biote Corp. Reaffirms Earnings Guidance for the Year 2024	May. 07	CI
B. Riley Ups Price Target on Biote to $10 From $9, Maintains Buy Rating	Apr. 05	MT
CORRECTION : --B. Riley Lowers Bitcoin Depot's Price Target to $4 From $6, Maintains Buy Rating	Apr. 03	MT
B. Riley Lowers biote's PT to $4 From $6 After Lower-Than-Expected Q4 2023 Results, Says California Regulations Hit Sales Outlook; Maintains Buy Rating	Mar. 26	MT
Biote Corp. completed the acquisition of Asteria Health.	Mar. 13	CI
Roth MKM Adjusts Price Target on Biote to $9 From $8, Maintains Buy Rating	Mar. 13	MT
Transcript : Biote Corp., Q4 2023 Earnings Call, Mar 12, 2024	Mar. 12
Biote Corp. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 12	CI
Biote Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 12	CI
Earnings Flash (BTMD) BIOTE Reports Q4 Revenue $45.7M, vs. Street Est of $45.7M	Mar. 12	MT
Biote Corp. Provides Revenue Guidance for 2024	Mar. 12	CI
B. Riley Securities Starts biote With Buy Rating, $9 Price Target	Feb. 20	MT
Jefferies Starts Biote With Buy Rating, $6.55 Price Target	Feb. 01	MT
Tech Stocks Drag Down Exchange-Traded Funds, Equity Futures Pre-Bell Friday	Jan. 26	MT

biote Corp. operates a practice-building business within the hormone optimization space. The Company provides the necessary components to enable Biote-certified practitioners to establish, build and implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The Biote Method is a comprehensive, end-to-end practice building platform that provides Biote-certified practitioners with the components specifically developed for practitioners in the hormone optimization space: Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (HRT) products, as well as digital and point-of-care marketing support. It also sells a complementary Biote-branded line of dietary supplements. The Biote Methodâs proprietary clinical decision support (CDS) software assists physicians in establishing individualized dosing for patients.

Sector

Professional Information Services

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company